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The multidrug resistance protein 2 (MRP2, ABCC2) gene may determine individual susceptibility to adverse drug reactions 
(ADRs) in the central nervous system (CNS) by limiting brain access of antiepileptic drugs, especially valproic acid (VPA). Our 
objective was to investigate the effect of ABCC2 polymorphisms on ADRs caused by VPA in Korean epileptic patients. We 
examined the association of ABCC2 single-nucleotide polymorphisms  and haplotype frequencies with VPA related to adverse 
reactions. In addition, the association of the polymorphisms with the risk of VPA related to adverse reactions was estimated 
by logistic regression analysis. A total of 41 (24.4%) patients had shown VPA-related adverse reactions in CNS, and the most 
frequent symptom was tremor (78.0%). The patients with CNS ADRs were more likely to have the G allele (79.3% vs. 62.7%, 
p = 0.0057) and the GG genotype (61.0% vs. 39.7%, p = 0.019) at the g.‒1774delG locus. The frequency of the haplotype 
containing g.‒1774Gdel was significantly lower in the patients with CNS ADRs than without CNS ADRs (15.8% vs. 32.3%, p 
= 0.0039). Lastly, in the multivariate logistic regression analysis, the presence of the GG genotype at the g.‒1774delG locus 
was identified as a stronger risk factor for VPA related to ADRs (odds ratio, 8.53; 95% confidence interval, 1.04 to 70.17). We 
demonstrated that ABCC2 polymorphisms may influence VPA-related ADRs. The results above suggest the possible use-
fulness of ABCC2 gene polymorphisms as a marker for predicting response to VPA-related ADRs.
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Introduction
Various forms of epilepsy are among the most common 
serious brain disorders and present through convulsion, 
autonomic movement, impaired consciousness, and more 
[1]. These neurological disorders affect an estimated 42 
million people of all ages worldwide [2]. The blood-brain 
barrier (BBB) has challenged the treatment of epilepsy, since 
many antiepileptic drugs (AEDs) are not effectively dis-
tributed to the vascular endothelium or, accordingly, to their 
targets in brain [3, 4]. The BBB, thought to be the first-line 
barrier to the disposition of drug from the blood to the brain 
[5], consists of the interplay of three major microvascular 
components. Tight junctions between the endothelial cells 
constitute the major permeability barrier. The overall 
biology of the barrier is shaped by the interactions between 
the endothelium and the pericytes/smooth muscle cells and 
the astrocyte foot processes that cover most of the abluminal 
surface of the microvasculature [6]. 
Drug pharmacokinetics is controlled by drug transporters, 
which regulate drug absorption, distribution, and excretion. 
Drug transporters are considered a second-line barrier for 
limiting drug disposition from the blood to the brain [7]. In 
brain capillary endothelial cells, multidrug resistance 
protein 1 (MDR1); multidrug resistance-associated protein 
1 (MRP1), MRP2, MRP4, and MRP5; and breast cancer 
resistance protein (BCRP) are among the many drug trans-
porters that might be expressed at the luminal side of the 
membrane [5, 8, 9]. MRP2, in particular, is over-expressed 
(about 225% greater) in drug-refractory temporal lobe 
epileptic patients with hippocampal sclerosis (HS) [5, 
10-12]. Drug reactions can be different between individuals 
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Demographic 
characteristics CNS ADR-Yes CNS ADR-No p-value
Gender
Male 18 (43.9) 66 (52.0) 0.473b
Female 23 (56.1) 61 (48.0)
Age (y) 36.32 ± 10.12 33.65 ± 10.27 0.149c
Seizure type
Partial 37 (90.2) 111 (87.4) 0.143b
Generalized 3 (7.3) 16 (12.6)
Undetermined 1 (2.4) 0 (0.0)
Epilepsies
LRE cryptogenic 20 (48.8) 76 (59.8) 0.345b
LRE symptomatic 17 (41.5) 35 (27.6)
Generalized idiopathic 2 (4.9)   11 (8.7)
Undetermined 2 (4.9) 3 (2.4)
Sclerosis 12 (29.3) 48 (37.8) 0.354b
History of AED
Carbamazepine (CBZ) 19 (46.3) 49 (38.6) 0.465b
Lamotrigine (LTG) 29 (70.7) 91 (71.7) >0.999b
Topiramate (TPM) 22 (53.7) 49 (38.6) 0.103b
Phenytoin (PHT)  7 (17.1) 23 (18.1) >0.999b
Drug response
Resistanta epilepsy 26 (63.4) 72 (56.7) 0.472b
Responsive epilepsy 15 (36.6) 55 (43.3)
No. of using drugs 3.76 ± 1.51 3.22 ± 1.40 0.039c,*
Values are presented as number (%).
VPA, valproic acid; CNS, central nervous system; ADR, adverse 
drug reaction; LRE, localization related epilepsy; AED, antiepi-
leptic drug. 
aDrug resistance was defined as the occurrence of at least four 
seizures during the previous year for patients who were being 
treated with more than three antiepileptic drugs at the maximally 
tolerable daily doses; bChi-square test was used; ct-test were used.
*p < 0.05 for comparison between CNS ADR-Yes and -No 
group.
Table 1. Demographic characteristics of epilepsy patients treated
with VPA
with the same AED blood concentrations and therapeutic 
levels, because drug distribution is influenced by variable 
levels of drug transporters. MRP2 is thought to play a more 
important role in the distribution of AEDs than other 
transporters in the epileptic brain [13]. MRP2 has been 
demonstrated to transport many AEDs, including valproate 
(VPA), carbamazepine (CBZ), phenytoin (PHT), and more 
[9, 14-17]. Valproic acid has become established as one of 
the most widely used AEDs in the treatment of both 
generalized and partial seizures in adults and children and is 
considered to be a substrate of MRP2 [9, 14-17]. Probenecid, 
an inhibitor of MRPs, has been shown to increase the 
concentration of valproic acid in the brain [18]. In animal 
models, TR‒ rats (MRP2 knockout) have lower VPA and 
VPA-glucuronide in their bile than control Wistar rats 
(which intrinsically express MRP2) [19].
Functional polymorphisms in genes encoding drug 
transporters can alter AED uptake, cerebral distribution, and 
efflux, resulting in individual differences in AED concen-
tration and effectiveness and/or the occurrence of adverse 
drug reactions (ADRs). Many functional single-nucleotide 
polymorphisms (SNPs) have been reported. For example, 
mRNA expression of the c.1446CG MRP2 genotype was 
recently revealed to be higher than the c.1446CC genotype in 
the liver [20]. In addition, the c.2302C ＞ T (exon 18, 
Arg768Trp) mutation is responsible for Dubin-Johnson 
syndrome [21, 22]. The c.2302C ＞ T and c.4348G ＞ A 
genotypes correlate with significantly lower MRP2 protein 
expression levels compared to wild-type and V417I [21]. The 
c.1249G ＞ A mutation significantly reduces the amount of 
MRP2 mRNA in human preterm placentas [23]. The g.‒
1774delG polymorphism has been linked with toxic 
hepatitis by our group [24]. In the present study, we 
investigated the association between the g.‒1774delG MRP2 
genotype and ADRs of the central nervous system (CNS) in 
VPA treatment groups.
Methods
Subjects
This retrospective study included 168 epileptic Korean 
patients who received VPA at Sinchon and Gangnam Seve-
rance Hospitals. Forty-one patients demonstrated VPA 
dose-related ADRs in the central nervous system (dizziness, 
headache, somnolence, diplopia, dysarthria, tremor, etc.), 
while the remainder (n = 127) did not. Patients who were 
diagnosed with chronic active epilepsy, West syndrome, 
Lennox-Gastaut syndrome, progressive myoclonic epilepsy, 
tuberous sclerosis, Sturge-Weber syndrome, hamartoma, or 
brain tumors were excluded. There were no statistical dif-
ferences in age, sex, response/non-response, and sclerosis 
between the two groups.
Demographic characteristics of the epileptic patients are 
presented in Table 1. DNA from control subjects (n = 110) 
was randomly selected from the DNA bank of the Korea 
Pharmacogenomics Research Network at Seoul National 
University. Blood samples were collected from each subject, 
and DNA was extracted using a QIAamp DNA blood mini kit 
(Qiagen GmbH, Hilden, Germany).
Genetic analysis
Polymorphisms of the MDR1, MRP, and BCRP genes in the 
Korean population were discovered by denaturing gradient 
gel electrophoresis, two-dimensional gene scanning, and 
direct PCR using methods similar to those described in a 
previous paper [24]. Genotype screening of each locus in 
control and epileptic patients was performed by the 
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SNaPshot or SNaPIT method (Applied Biosystems, Foster 
City, CA, USA), according to the protocols supplied by the 
manufacturer.
Statistical analysis
Haploview software (version 3.2) was used to design 
MRP2 haplotype constructs and analyze major or minor 
haplotypes based on a standard expectation-maximization 
algorithm. Allele and genotype frequencies of transporter 
polymorphisms were assessed using chi-square tests (ver-
sion 11.5 for Windows; SPSS Inc., Chicago, IL, USA). 
Logistic regression
The strength of the association between dose-related CNS 
ADR patients and the presence of the G allele at the g.‒1774 
region was evaluated as the odds ratio (OR) obtained with 
logistic regression analysis (SPSS version 11.5). ORs were 
adjusted for gender, age, HS, use of AEDs (larmotrigene, 
CBZ, PHT, and topiramate), and the presence of the G allele 
at the g.‒1774 promoter region. 
Cell culture
SH-SY5Y (ATCC, Manassas, VA, USA), a human brain 
neuronal cell line originated from a neuroblastoma, was a 
gift from Dr. In Suk Kim, Yonsei University College of 
Medicine, Seoul, Korea. SH-SY5Y cells were maintained 
with Dulbecco’s modified Eagle medium supplemented with 
10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 
1% PS (100 units penicillin, 100 μg streptomycin, Gibco, 
Grand Island, NY, YSA) and were cultured under pre-
confluent monolayer conditions in 100-mm-diameter poly- 
d-lysine-coated culture dishes at 37oC with 5% humidified 
CO2.
Plasmid preparation of MRP2 promoter
A pGL3 basic vector containing the human MRP2 pro-
moter region (about 2.3 kb, ‒2314 to +348 relative to the 
translation initiation site) was constructed by our group in a 
previous study from homozygotic persons with MRP2 
haplotypes 1, 2, and 3 [24]. The g.‒1774delG polymorphism 
is located in haplotype 1, and the g.‒24C ＞ T polymorphism 
is located in haplotype 3. The reporter vector of a minor 
haplotype variant containing only the g.‒1549G ＞ A varia-
tion was constructed using mutagenic primers, introducing 
a ‒24 T → C change to the plasmid of haplotype 3 containing 
both g.‒1549G ＞ A and g.‒24C ＞ T variations. Haplotype 2 
includes no polymorphism (wild-type). In short, a total of 
five clones were prepared: pGL3 basic; haplotypes 1, 2, and 3; 
and g.‒1549A alone.
Dual luciferase assay
The pGL3 basic vector containing WT MRP2 promoter 
variants was transfected into SH-SY5Y cells to measure the 
activity of the MRP2 promoter with and without VPA 
(P4543; Sigma Aldrich, St. Louis, MO, USA). The day before 
transfection, 0.2 × 106 SH-SY5Y cells were seeded in a 
12-well plate in order to reach 90‒95% confluence at the time 
of transfection; 1.6 μg of pGL3-MRP2, including the variants 
and mock, was added to wells with Lipofectamine 2000 
(Invitrogen). Vector-containing Renilla luciferase was co- 
transfected in order to confirm the transfection efficiency of 
the pGL3-MRP2 vector. After a 3- to 5-h incubation, cells 
were washed with phosphate-buffered saline (PBS; Invitro-
gen) and incubated at 37oC with 5% humidified CO2 for 24 
h. Reporter activity was measured using the Dual Luciferase 
Reporter Assay system (Promega Corporation, Madison, 
WI, USA). After removing the growth medium, cells were 
washed with PBS, and the plates were placed on a rocking 
platform shaker with 250 μL of 1 × passive lysis buffer per 
well for 15 min. Lysates were transferred to an e-tube, and 
luciferase binding was performed with 50 μL LARII and 10‒
50 μL cell lysate in a 96-well assay plate (Costar; Corning 
Incorp., Corning, NY, USA). After 10 s, light emission was 
measured using a luminometer (Berthold Technologies, 
Wildbad, Germany), and Stop & Glo was added to each well 
to stop firefly luciferase activity and evoke Renilla luciferase 
activity.
Results
SNP association with drug response or resistance
Drug resistance was defined as the occurrence of at least 
four seizures over the year before recruitment, with trials of 
more than three appropriate AED, at maximal tolerated 
doses, based on the occurrence of clinical side effects at 
supra-maximal doses [25]. The patients were classified as 
either responsive or resistant to drug therapy. We did not 
find any significant associations between the selected drug 
transporter SNPs and either group.
Clinical characteristics of epilepsy patients
A total of 41 (24%) epileptic patients had ADRs of the 
CNS, and 127 (76%) epileptic patients did not (non-ADR). 
The demographic characteristics are listed in Table 1. The 
gender frequency, drug response, and the average age of drug 
use between the two groups were similar. (p ＞ 0.05) 
Subjects without ADRs used fewer drugs than those with 
ADRs (p = 0.039). The most frequent symptom out of 14 
types of ADRs to VPA use was tremors (78.0%). Based on 
logistic regression, ADRs were more likely to occur in 
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Variant Allele Control
Epilepsy patient
p-value
CNS ADR-Yes CNS ADR-No
g.‒1774delG G 146 (66.4) 65 (79.3) 158 (62.7) 0.0057**
del  74 (33.6) 17 (20.7)  94 (37.3)
g.‒1549G > A G 174 (79.1) 59 (72.0) 199 (80.2) 0.1151
A  46 (20.6) 23 (28.0)  49 (19.8)
g.‒24C > T C 182 (72.7) 54 (65.9) 198 (78.0) 0.0278*
rs717620 T  38 (17.3) 28 (34.1)  56 (22.0)
g.‒23G > A G 215 (97.7) 82 (100.0) 253 (99.6) 0.5693
A   5 (2.3)  0 (0.0)   1 (0.4)
c.1249G > A G 199 (90.5) 73 (89.0) 235 (92.5) 0.3194
(p.V417I, rs2273697) A  21 (9.5)  9 (11.0)  19 (7.5)
c.1457C > T C 217 (98.6) 82 (100.0) 254 (100.0) -
(p.T486I) T   3 (1.4)  0 (0.0)   0 (0.0)
c.2620 + 3A > G A 220 (100) 82 (100.0) 254 (100.0) -
G   0  0 (0.0)   0 (0.0)
c.2934G > A G 209 (95.0) 79 (96.3) 244 (96.1) 0.9095
(p.S978S, rs3740070) A  11 (5.0)  3 (3.7)  10 (3.9)
c.3972C > T C 169 (76.8) 53 (64.6) 192 (75.6) 0.0522
(p.I1324I, rs3740066) T  51 (23.2) 29 (35.4)  62 (24.4)
c.4147 ‒ 35G > A G 217 (98.6) 80 (97.6) 253 (99.6) 0.0869
A   3 (1.4)  2 (2.4)   1 (0.4)
c.4508 + 12G > A G 218 (99.1) 82 (100.0) 254 (100.0) -
A   2 (0.9)  0 (0.0)   0 (0.0)
Values are presented as number (%).
CNS, central nervous system; ADR, adverse drug reaction. 
p-values were obtained by comparisons between CNS ADR-Yes and -No groups using chi-square or Fisher’s exact test (expected 
cell value <5). *p < 0.05, **p < 0.01.
Table 2. Allele frequencies of the MRP2 polymorphisms
patients with g.‒1774delG (presence of G allele), which had 
the highest OR (9.10) among the considered factors (p ＜ 
0.05).
Genetic polymorphisms of MRP2 in the Korean 
population
MRP polymorphisms covering all MRP2 exons, exon- 
intron junctions, and the promoter region up to ‒2.3 Kb from 
the translation initiation site have been described in the 
Korean population [24]. We investigated 11 of the poly-
morphisms from previous studies in 110 healthy control 
people and 168 epileptic patients. We found four promoter, 
four exonic, and three intronic polymorphisms among them.
Relationship between genotypes of MRP2 and CNS 
ADRs to VPA
Allele frequencies of the MRP2 polymorphisms are shown 
in Table 2. Non-ADR patients were more likely to have the 
deletion allele instead of the G allele at g.‒1774 when 
compared with patients with CNS ADRs (p = 0.0057; ADR, 
20.7%; non-ADR, 37.3%). The frequency of the T allele at 
g.‒24 was higher in patients with CNS ADRs than those 
without (p = 0.0274; ADR, 34.1%; non-ADR, 22.0%). The 
difference between the groups based on g.‒24C ＞ T frequen-
cies was not significant after Bonferroni’s correction, while 
the difference based on g.‒1774delG frequencies remained 
significant.
The genotype frequencies of each polymorphism are 
shown in Table 3. Genotype frequency distributions were 
consistent with Hardy-Weinberg equilibrium (each p ＞ 0.5). 
The ADR group patients were more likely to have a GG 
genotype than a deldel genotype at g.‒1774delG compared to 
the non-ADR group (p = 0.023, homo GG and deldel p = 
0.0146). The TT and CT genotype frequencies at g.‒24C ＞ T 
were higher in patients with CNS ADRs than non-ADR 
patients (p = 0.035, hetero CT → TT p = 0.019). 
The frequencies of haplotypes present in at least 10% of 
the population are presented in Table 4. Haplotype fre-
quencies of the MRP2 polymorphisms at all site. The fre-
quency of haplotype 1 was significantly higher in patients 
without CNS ADRs (32.3%) than those with ADRs (15.8%) 
(p = 0.0039). The frequency of haplotype 3 was higher in 
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ID ‒1774Gdel 
‒1549
G/A ‒24C/T ‒23G/A V471I T486I
2620+
3A/G
2934
G/A
3972C/
T
4147－
35G/A
4508+
12G/A
Group
Control CNS ADR-Yes
CNS ADR
-No
1 del G C G V C A G C G G 69 (31.3) 13 (15.8)  82 (32.3)**
2 G G C G V C A G C G G 54 (24.4) 24 (29.0) 65 (25.7)
3 G A T G V C A G T G G 31 (14.2) 18 (22.3)* 29 (11.4)
4 G G C G I C A G C G G 19 (8.7)  8 (9.3)  17 (6.7)
5 G G T G V C A G T G G 4 (1.7)  9 (10.6)  25 (9.8)
ㆍ ㆍ ㆍ ㆍ ㆍ ㆍ ㆍ ㆍ ㆍ ㆍ ㆍ ㆍ ㆍ ㆍ ㆍ
Total 220 82 254
Values are presented as number (%).
Haplotypes were assembled using a software based on the Bayesian algorithm (Haploview, ref. No.). Major haplotypes showing 
over 5% frequency in control and epilepsy patients are presented in this table. Haplotype identification (ID) numbers were assigned 
according to the frequency of haploid genes analyzed in this study. 
CNS, central nervous system; ADR, adverse drug reaction. 
Differences between CNS ADR-Yes and -No groups were analyzed by chi-square analysis. *p = 0.0139, **p = 0.0039.
Table 4. Frequency of MRP2 haplotypes in control and epilepsy patients
Variant Control
Epilepsy patient
p-value
CNS ADR-Yes CNS ADR-No
g.‒1774delG +/+a  50 (45.5) 25 (61.0)  50 (39.7)   0.019*
+/‒  46 (41.8) 15 (36.6)  58 (46.0)
 ‒/‒  14 (12.7)  1 (2.4)  18 (14.3)
g.‒1549G > A +/+  66 (60.0) 21 (51.2)  82 (66.1)   0.440
+/‒  42 (38.2) 17 (41.5)  35 (28.2)
 ‒/‒   2 (1.8)  3 (7.3)   7 (5.6)
g.‒24C > T +/+  74 (67.3) 17 (41.5)  79 (62.2)   0.243
rs717620 +/‒  34 (30.9) 20 (48.8)  40 (31.5)
 ‒/‒   2 (1.8)  4 (9.8)   8 (6.3)
g.‒23G > A +/+ 105 (95.5) 41 (100.0) 126 (99.2) >0.999
+/‒   5 (4.5)  0 (0.0)   1 (0.8)
c.1249G > A +/+  92 (83.6) 32 (78.0) 109 (85.8) >0.999
(p.V417I) +/‒  15 (13.6)  9 (22.0)  17 (13.4)
rs2273697 ‒/‒   3 (2.7)  0 (0.0)   1 (0.8)
c.1457C > T +/+ 107 (97.3) 41 (100.0) 127 (100.0) -
(p.T486I) +/‒   3 (2.7)  0 (0.0)   0 (0.0)
c.2620 + 3A > G +/+ 110 (100.0) 41 (100.0) 127 (100.0) -
c.2934G > A +/+ 100 (90.9) 38 (92.7) 117 (92.1) -
(p.S978S) +/‒   9 (8.2)  3 (7.3)  10 (7.9)
rs3740070 ‒/‒   1 (0.9)  0 (0.0)   0 (0.0)
c.3972C > T +/+  61 (55.5) 17 (41.5)  74 (58.3)   0.164
(p.I1324I) +/‒  47 (42.7) 19 (46.3)  44 (34.6)
rs3740066 ‒/‒   2 (1.8)  5 (12.2)   9 (7.1)
c.4147 ‒ 35G > A +/+ 107 (97.3) 39 (95.1) 126 (99.2)   0.141
+/‒   3 (2.7)  2 (4.9)   1 (0.8)
c.4508 + 12G > A +/+ 108 (98.2) 41 (100.0) 127 (100.0) -
+/‒   2 (1.8)  0 (0.0)   0 (0.0)
Values are presented as number (%).
CNS, central nervous system; ADR, adverse drug reaction. 
a+, major allele; ‒, minor allele. 
p-values (+/+ vs. ‒/‒) were obtained by comparisons between CNS ADR-Yes and -No groups using chi-square or Fisher’s exact 
test (expected cell value < 5). *p < 0.05. 
Table 3. Genotype distribution of MRP2 variants in control and epilepsy patients
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Variable Odd ratio (95% CI) p-value
Presence of g.–1774 G/Ga 3.379 (1.177–9.701) 0.0363*
Genderb  0.72 (0.33–1.53) 0.3909
Age  1.03 (0.99–1.07) 0.0929
Sclerosis  0.56 (0.24–1.31) 0.1835
Valproic acid dose 1.002 (1.000–1.003) 0.0795
Carbamazepine _use  1.46 (0.67–3.17) 0.3368
Lamotrigine _use  0.83 (0.34–2.03) 0.6867
Topiramate _use  1.71 (0.77–3.81) 0.1896
Phenytoin _use  0.68 (0.24–1.88) 0.4548
CNS, central nervous system; ADR, adverse drug reaction; VPA, 
valproic acid; CI, confidence interval.
aReference category: Del/Del; bReference category: female, 
Logistic regression analysis was done using SPSS version 11.5. 
*p < 0.05.
Table 5. Multiple logistic regression analysis for the determinants
of CNS ADRs caused by VPA
Fig. 1. Luciferase activity of MRP2 promoter variants. Valproic acid
(VPA) stimulated MRP2 promoter activity. The g.‒1774del (-GCG)
variant was more activated than g.‒1774G (GGCG) in cells treated
with 3 mM VPA. *p ＜ 0.05.
patients with CNS ADRs than those without (p = 0.0139), 
but this difference was no longer significant after Bonfer-
roni’s correction was applied. 
Measurement of MRP2 promoter activity
VPA stimulated MRP2 promoter activity about 10-fold. 
The epileptic patients with ADRs of the CNS had less 
haplotype 1 (containing g.‒1774del) than the epileptic 
patients with no ADRs. By inference, the g.‒1774G allele, a 
major allele of the MRP2 promoter sequence, was associated 
with ADRs of the CNS in patients treated with VPA. 
Epileptic patients with g.‒1774del instead of g.‒1774G were 
more likely to be resistant to VPA-related ADRs, probably 
because the g.‒1774del allele produced higher MRP2 
promoter activity than g.‒1774G, leading to more MRP2 
proteins in the brain tissue after VPA treatment. The 
presence of more MRP2 affected the distribution of AEDs 
(especially VPA) from the blood to the brain, resulting in the 
appearance of VPA-related ADRs in patients with g.‒1774G 
rather than g.‒1774del. Our luciferase assay data supported 
this hypothesis. There was no difference in luciferase activity 
between g.‒1774del and the others (g.‒1774G, g.‒24C＞T, g.
‒1549G ＞ A) with non-VPA treatment. Luciferase activity 
was different, however, following 3 mM VPA treatment; g.‒
1774del promoter (haplotype 1) activity was 134% higher 
than g.‒1774G promoter (haplotype 2) activity (n = 5; p ＜ 
0.05 by t-test). Further, the g.‒1774del MRP2 promoter 
increased 1,014% with 3 mM VPA treatment compared to 
non-VPA treatment. However, the g.‒1774G MRP2 promoter 
also increased 816% with 3 mM VPA treatment compared to 
non-VPA treatment. The change of g.‒1774G → del in-
creased the expression of MRP2 in neuronal SH-SY5Y cells 
treated with 3 mM VPA (Fig. 1). 
Factors influencing ADRs to VPA
Many factors, including gender; age; treatment with CBZ, 
lamotrigine, PHT, or topiramate; and HS, did not influence 
ADRs. The presence of the genotype G/G at the g.‒1774 
region of the MRP2 promoter influenced ADRs to VPA in 
epileptic patients. Logistic regression showed that the G/G 
correlated independently with ADRs to VPA (p ＜ 0.05; OR, 
9.102; 95% confidence interval, 1.111 to 73.378). The 
del/del allele was the reference category (Table 5). The G/G 
genotype at g.‒1774 might influence lower expression of 
MRP2 than del/del in the brain, leading to ADRs. 
Discussion
The selective cellular barrier controlling drug delivery into 
the brain has been identified by the over-expression of MRP2 
in capillary endothelia, astrocytes, and neuronal cells in 
previous studies [5, 26, 27]. In this study, we found that the 
g.‒1774del genotype in the promoter region up-regulated 
the expression of MRP2. Patients with g.‒1774del showed 
resistance to ADRs by increasing the expression of MRP2, 
followed by a decrease of drug concentration in the brain. 
Our data supported this hypothesis and verified an 
association between g.‒1774delG and ADR.
The difference of luciferase activity between g.‒1774G and 
g.‒1774del in neuronal SH-SY5Y cells was not large. 
However, they showed extensive differences by statistical 
analysis (p ＜ 0.05 by t-test). Because the expression level of 
MRP2 is lower in brain neuronal tissue than in hepatic 
tissue, even a little change is thought to be important. The 
luciferase assay of MRP2 promoter activity has not been 
conducted in brain capillary endothelial cells yet. In this cell 
line, SNP function is thought to be more effective, since 
MRP2 is more highly expressed in endothelial cells than in 
neuronal cells [28]. 
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In reality, if MRP2 and other transporters are over- 
expressed in the brain, most patients should be not only 
non-ADR but also resistant to drug therapy. However, allele 
and genotype frequencies of g.‒1774delG were not different 
between drug-resistant and drug-responsive patients (p ＞ 
0.05). The absence of a strict definition of drug-resistant 
epilepsy may have weakened the statistical analysis. The 
selected grouping was only a foundation for retrospective 
chart review. If the definition was stricter－for example, at 
least one seizure per year or non-seizure over the year－the 
different frequencies of g.‒1774delG within each group 
would have been more significant. An accurate study design 
and definitions are a key part of effective pharmacogenomic 
studies [2]. Standards for association studies in pharma-
cogenomics have been presented in previous studies [2].
In spite of the retrospective study design, an association 
with g.‒1774delG was noticeably significant. This SNP was 
reported previously in our group in relation to toxic hepatitis 
[24]. In that study, the g.‒1774del genotype caused lower 
expression of MRP2 than g.‒1774G in a human hepatocyte- 
originated cell line (HepG2). This finding is contrary to the 
results of the present study. There are different known 
transcription factors in hepatocytes and neuronal and 
endothelial cells. The promoter activity in the cells trans-
fected with a g.‒1774G (haplotype 2) clone was about 100 
times stronger than those transfected with the control vector 
in hepatic cells. A strong transcriptional activator is present 
in hepatocytes. However, the difference in promoter activity 
between g.‒1774G and mock control was lower in neuronal 
SH-SY5Y cell lines. Neuronal transcription factors are 
expected to be weaker than those in hepatocytes. The bind-
ing sequence is “AAAAACAACAAGATAA” (the underlined 
C is the anti-sense sequence at g.‒1774G). Transcription 
factors that are known to bind this sequence are GATA-1, 
Evi-1, FOXO, HNF3, and more (Genomatix software GmbH). 
Each tissue-specific transcription factor binds this sequence 
and induces different levels of MRP2 expression. For 
example, HNF3, a common activator in hepatocytes, was 
thought to activate MRP2 expression through binding with 
g.‒1774G rather than g.‒1774del. Consequently, the ex-
pression of MRP2 of g.‒1774del would be lower than g.‒
1774G. In contrast, if neuronal cell transcriptional activators 
were more likely to bind g.‒1774del over g.‒1774G, neuronal 
expression of MRP2 of g.‒1774del would be higher than g.‒
1774G. The factors that bind to this region have yet to be 
determined. Previous studies have referred to the different 
binding factors of this region in human coronary artery 
smooth muscle cells without specific identification.
In the present study, a luciferase assay demonstrated that 
VPA stimulated the activity of the MRP2 promoter in 
SH-SY5Y cells. VPA is a well-known histone deacetylase 
(HDAC) inhibitor that induces apoptosis in cancer cells [29, 
30]. In normal cells, however, VPA activates chromosomal 
transcriptional ability by inhibiting HDAC. Chromosomal 
DNA forms a compact nucleosome with histone proteins 
and needs to be unpacked in order to start transcription. 
HDAC removes the acetyl group in acetyl-lysine residues 
and biologically inhibits the activity of transcription [31]. In 
neuronal SH-SY5Y cells, VPA could activate the MRP2 
promoter by inhibiting HDAC. MRP2 has farnesoid X 
receptor, retinoid X receptor (RXR), and peroxisome pro-
liferator-activated receptor/RXR binding regions. VPA inte-
racts with these proteins and regulates the expression level 
of MRP2 protein [32, 33].
P-gp polymorphisms have repeatedly been associated 
with drug response in epilepsy [25, 34-37]. Up to now, 
however, the only functional studies of MRP2 have been 
conducted in a knockout animal model [38]. This report is 
the first investigation to show an association between MRP2 
polymorphisms and ADRs in epilepsy. These results may be 
useful in tailoring AED medication. The G allele of the MRP2 
promoter was associated with ADRs to VPA in Korean 
epileptic patients. The del allele of MRP2 protected the brain 
against adverse effects of VPA by over-expressing MRP2 in 
brain neuronal cells. These data will help design therapy to 
minimize ADRs in epileptic patients and aid in the develop-
ment of new AEDs. However, further independent repli-
cation studies are needed to unequivocally confirm the 
association.
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